The transcription factor NFB regulates inflammatory and other cellular responses. In non-stimulated cells, NFB is linked to its inhibitor IB, which plays a major role in controlling NFB activity. Here, the gene promoter region of the major inducible IB component (IB-␣) was studied to identify single nucleotide polymorphisms (SNPs), and to test if these are associated with risk of two diseases involving inflammation and fibrosis (trachoma and silicosis). Three SNPs were identified at positions −881, −826 and −297 relative to the transcription start site. The position −297 is close to two NFB binding sites, B2 and B3, but the alleles were not associated with either disease. Alleles at positions −881 and −826 were in complete linkage disequilibrium with each other, and the rare haplotype was significantly less frequent among patients with trachoma compared to controls, although there was no difference in frequencies between silicosis patients and controls. Genes and Immunity (2001) 2, 153-155.
Nuclear factor kappa b (NFB) is an important transcription factor, which can activate the expression of many genes involved in inflammatory and immune responses, cellular proliferation, development and apoptosis. 1 In non-stimulated cells, NFB is present in its inactive form in the cytoplasm, tightly linked to its inhibitor I kappa B (IB). The importance of IB in the process of NFB regulation has been extensively described. IB is composed of several sub-units, and its abundance is known to be controlled by post-translational processes including phosphorylation, 2, 3 but it may also be under transcriptional regulation. Overexpression of one of the IB components (IB-␣) has been implicated in the development of lymphoma, apparently due to a mutation in the coding region of the IB-␣ gene 4 on chromosome 14. It is possible that allelic differences in the IB-␣ promoter may also affect IB-␣ expression and thus influence the regulation of inflammatory responses to infection or injury. Here, single nucleotide polymorphisms (SNPs) were discovered in the IB-␣ promoter region, and these were tested for association with two different diseases involving inflammation, tissue damage and fibrosis. lung disease resulting from inhalation of crystalline silica particles. 6 A single sequence of the human IB-␣ promoter region was previously available (accession number U08468). 7 To screen for sequence polymorphism, direct sequencing of purified PCR products (representing nucleotides −1034 to +28) was first performed on DNA from a panel of 16 Gambian adult donors. Three SNPs were detected at positions −881, −826 and −297 from the transcription start site. Six constant differences from the database sequence were also found at positions −984, −644, −582, −581, −421 and −404 (probably due to errors in the database sequence, but the possibility that this was an unusual type not seen in the Gambia is not excluded). Each of the SNPs and the constant differences were confirmed by cloning and sequencing both alleles from five individuals, revealing three −881/−826/−297 haplotypes (ACC, ACT and GTT). The −297 polymorphism is situated close to sites of NFB transcription factor-DNA interaction, 7, 8 with B2 and B3 motifs respectively located only 13 bp upstream and 72 bp downstream 8 ( Figure 1 ). To test for disease associations, 393 Gambians (199 patients with scarring trachoma and 194 controls matched by age, sex and village) and 157 South African miners (82 silicotic patients and 75 age-and occupation-matched controls) were typed for the three IB-␣ promoter SNPs. Design and recruitment of these two case-control studies has been described previously. 9, 10 There were no significant differences in proportions of genotypes between cases and controls for either disease (Table 1) . However, a difference was seen in allele frequencies at positions −881 and −826 between trachoma cases and controls. The −881G and −826T alleles are in complete linkage disequilibrium with each other Figure 1 IB-␣ promoter region sequence. NFB-binding motifs B1, B2 and B3 are boxed. 7 The three single nucleotide polymorphisms (SNPs) are shown in bold with the rare allele nucleotide given above. The −297 polymorphism is located only 13 bp downstream of the B2 motif and 72 bp upstream of the B3 motif. The TATA box is underlined and the transcription start site is in bold and labelled as position +1. Sequences on which PCR amplification primers were based are underlined (PCR was performed with 30 cycles of 95°C for 30 s, 62°C for 30 s, and 72°C for 60 s). Sequencing in both directions was performed on purified PCR products and cloned DNA in pGEM-T Easy Vector (Promega, Southampton, UK) by Big Dye cycle sequencing (Applied Biosystems, Warrington, UK). Cloned sequences determined three different −881/−826/−297 haplotypes: ACC, ACT and GTT (sequence accession numbers AJ300572-4).
(P Ͻ 0.001), existing as a single haplotype which was at a significantly lower frequency in trachoma patients compared with controls (0.030 vs 0.060; P = 0.046). The rare allele at position −297, although not associated with disease, was more common in South Africans than Gambians (frequency of −297T = 0.035 and 0.011 respectively; P = 0.008). Four −881/−826/−297 haplotypes were determined: ACC, GTC, ACT and GTT (at respective frequencies of 0.950, 0.038, 0.005 and 0.006 in The Gambia; 0.934, 0.025, 0.025, and 0.016 in South Africa).
The lower frequency of the IB −881G/−826T haplotype in trachoma cases suggests that this could have a protective role against development of scarring trachoma. However, as this haplotype was not associated with a lower risk of silicosis, it may be argued that it is unlikely to affect mechanisms proposed to be common to both diseases, including NFB-mediated inflammatory responses involving over-production of TNF-␣. 10, 11 The overall low frequencies of −881G, −826T and particularly the −297T allele means that each disease association study is limited in power, and it is recommended that other disease association studies are undertaken, as well as transcriptional studies, to test for effects of these IB-␣ polymorphisms. . See text for analysis of allele frequencies. Sequence specific oligonucleotide probes (SSOP) were designed to discriminate the SNP alleles at positions −881, 5ЈGGGAGCACAATGTAGGTC3Ј/5ЈGGGAGCACAGTGTAGGTC3Ј; −826, 5ЈAGCTACTCTGCTATTGCA3Ј/5ЈAGCTACTCTGT TATTGCA3Ј; −297, 5ЈGGCTCACTTGCAGAGGGA3Ј/5ЈGGTTCACTTGCAGAGGGA3Ј. Probes were 3Ј-end labelled with digoxigenin, and used for allele-specific hybridisation to dot blots as described for other genes 9 (high stringency washing with buffer containing 3 M Tetramethylammonium Chloride was performed at 58°C for the −881 probes, and at 56°C for the −826 and −297 probes).
